BerGenBio AS of Norway has completed an $8.8 million Series A financing round to take its lead cancer compound into the clinic and develop a companion diagnostic. The lead investors are Sarsia Seed AS and Investinor AS. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
